

Recombinant Human soluble Tumor Necrosis Factor-Related Apoptosis-inducing Ligand Receptor-2/TNFRSF10B

Information

Gene ID	8795
Accession #	O14763
Alternate Names	soluble TRAIL Receptor-2, DR5, TNFRSF10B, KILER, TRICK2A, TRICKB
Source	Escherichia coli.
M.Wt	Approximately 14.8 kDa, a single non-glycosylated polypeptide chain containing 132 amino acids.
AA Sequence	ESALITQQDL APQQRAAPQQ KRSSPSEGLC PPGHHISEDG RDCISCKYQG DYSTHWNDLL FCLRCTRCDS GEVELSPCTT TRNTVCQCEE GTFREEDSPE MCRKRTGCP RGMVKVGDCT PWSDIECVHK ES
Appearance	Sterile Filtered White lyophilized (freeze-dried) powder.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles - 12 months from date of receipt, -20 to -70 °C as supplied - 1 month, 2 to 8 °C under sterile conditions after reconstitution - 3 months, -20 to -70 °C under sterile conditions after reconstitution
Formulation	Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Biological Activity	Fully biologically active when compared to standard. rHusTRAIL-R2 reduced the production of LPS-induced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10 ng/mL) but in the presence of rHusTRAIL-R2, TRAIL-induced TNF is suppressed.
Shipping Condition	Gel pack.
Handling	Centrifuge the vial prior to opening.
Usage	For Research Use Only! Not to be used in humans.

Components and Storage

Components	10μg	100μg	500μg
Recombinant Human soluble Tumor Necrosis Factor-Related Apoptosis-inducing Ligand Receptor-2/TNFRSF10B	10μg	100μg	500μg

Use a manual defrost freezer and avoid repeated freeze-thaw cycles

- 12 months from date of receipt, -20 to -70 °C as supplied
- 1 month, 2 to 8 °C under sterile conditions after reconstitution
- 3 months, -20 to -70 °C under sterile conditions after reconstitution

Quality Control

Purity	> 97 % by SDS-PAGE and HPLC analyses.
Endotoxin	Less than 1 EU/ μ g of rHusTRAIL-R2 as determined by LAL method.

Description

Tumor necrosis factor-related apoptosis-inducing ligand Receptor 2 (TRAIL-R2) is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells. TRAIL-R2 has been shown to be associated with a decrease in the survival rates of breast cancer patients.

Reference

1. Pordzik S, Petrovici K, Schmid C, et al. 2011. Hematology, 16: 341-50
2. Tseng HY, Chen LH, Ye Y, et al. 2012. Carcinogenesis, 33: 1871-81
3. Bae SI, Cheriyaath V, Jacobs BS, et al. 2008. Oncogene, 27: 490-8
4. Camidge DR. 2008. Expert Opin Biol Ther, 8: 1167-76.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

